Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 55Recurrence 14Neoplasms, Plasma Cell 9Primary Myelofibrosis 3Polycythemia Vera 3Neoplasms 3Waldenstrom Macroglobulinemia 2Plasmacytoma 2Myeloproliferative Disorders 2Hematologic Diseases 2Thrombocytosis 1Thrombocythemia, Essential 1Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Sarcoma 1Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Glioma 1Ependymoma 1Central Nervous System Neoplasms 1

Interventions

Cisplatin 4Pemetrexed 3Etoposide 3Topotecan 2Gemcitabine 2Carboplatin 2vosaroxin 1vinflunine 1veliparib 1taxane 1pomalidomide 1pembrolizumab 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1apalutamide 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1Temozolomide 1Radiation 1RRx-001 1Positron-Emission Tomography 1Podophyllotoxin 1Platinum 1Paclitaxel 1Irinotecan 1Histamine Antagonists 1GSK2879552 1Epinephrine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Small Cell × pomalidomide × Clear all
NCT00537511 2019-11-19

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Celgene

Phase 1/2 Terminated
22 enrolled 13 charts

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡